Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

516

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

December 14, 2028

Study Completion Date

December 14, 2030

Conditions

Breast Cancer

Interventions

DRUG

Fulvestrant combined with Pyrotinib

Fulvestrant 500mg was injected intramuscularly on D1, D15, D28 and D28 Pyrotinib 400mg daily

DRUG

Capecitabine combined with Pyrotinib

Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily

Trial Locations (1)

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT04646759 - Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter